The widespread increase in broad-spectrum antimicrobial resistance is making it more di cult to treat gastrointestinal infections. Enteroinvasive Escherichia coli is a prominent etiological agent of bacillary dysentery, invading via the fecal-oral route and exerting virulence on the host via the type III secretion system. IpaD, a surface-exposed protein on the T3SS tip that is conserved among EIEC and Shigellae, may serve as a broad antigen for bacillary dysentery protection. For the rst time, we present an effective framework for improving the expression level and yield of IpaD in the soluble fraction for easy recovery, as well as ideal storage conditions, which may aid in the development of new protein therapies for gastrointestinal infections in the future. To achieve this, uncharacterized full length IpaD gene from EIEC was cloned into pHis-TEV vector and induction parameters were optimised for enhanced expression in the soluble fraction. After a nitychromatography based puri cation, 61% pure protein with a yield of 0.33 mg per litre of culture was obtained.The puri ed IpaD was kept the secondary structure with predominant α-helical structure at 4°C, -20°C, and -80°C using 5% sucrose as cryoprotectants during storage which is the fundamental parameter for protein-based therapeutics.